Global healthcare major Zydus Lifesciences is set to make a major move in diabetes and obesity care, planning to launch its Semaglutide Injection in India on Day 1 of patent expiry under the brand names SEMAGLYNTM, MASHEMATM, and ALTERMETM. 

 

The Drug Controller General of India (DCGI) has already approved the drug for the treatment of Type 2 Diabetes Mellitus and Obesity.

 

Zydus’ offering stands out with a groundbreaking, indigenously developed drug-delivery system. Unlike existing therapies that require patients to buy multiple single-dose pens, Zydus will introduce an adjustable, single reusable pen capable of delivering all approved dosage strengths. The innovation promises to simplify treatment, improve patient adherence, and reduce the overall cost of therapy.

 

Speaking on the launch, Managing Director Sharvil Patel said, "Zydus’ innovative offering of Semaglutide injection is a testament to our enduring commitment to patient-centric innovation. We are not just planning to bring a critical therapy to market, we are aiming to elevate the standard of care. By introducing a first-of-its-kind drug delivery mechanism in India, we plan to simplify the treatment. This leap in convenience will drive better long-term adherence and, ultimately, significantly improved clinical outcomes for patients."

 

With exclusive rights to this novel device, Zydus’ prefilled cartridge pen is set to redefine patient experience by combining versatility, ease-of-use, and affordability.